Physician profile
Brandon R Litzner
NPI 1619297769
$16,366.72
in general payments reported to CMS, 2019-2025
44 companies · $3,549 in 2025
The $3,549 reported for 2025 was more than what 92% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $742 · 2021: $1,582 · 2022: $2,917 · 2023: $3,078 · 2024: $3,504 · 2025: $3,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,877 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,877.18 |
| Education | $252.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,666.28 | 2019-2025 | |
| Janssen Biotech, INC. | $2,378.88 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,500.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,045.04 | 2022-2025 | Sotyktu |
| Amgen INC. | $1,017.25 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $983.77 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $875.58 | 2019-2025 | Winlevi, Blu-U, Ilumya |
| Genzyme Corporation | $687.20 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $670.21 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $666.45 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $516.44 | 2019-2025 | Bimzelx |
| Dermavant Sciences, INC. | $500.60 | 2023-2024 | Vtama |
| Incyte Corporation | $277.48 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $153.07 | 2021-2025 | |
| Almirall LLC | $124.28 | 2021-2023 | Seysara |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Litzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.